Are breast cancer subtypes prognostic for nodal involvement and associated with clinicopathologic features at presentation in early-stage breast cancer?

Annals of Surgical Oncology

Volumn 20, Issue 9, 2013, Pages 2866-2872

  Jones, Tiffanie ^a   Neboori, Hanmanth ^b   Wu, H ^b   Yang, Qifeng ^c   Haffty, Bruce G ^b   Evans, Susan ^a   Higgins, Susan ^a   Moran, Meena S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; BREAST CANCER; BREAST METASTASIS; BREAST SURGERY; CANCER PROGNOSIS; DISEASE FREE SURVIVAL; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS FREE SURVIVAL; REVIEW; TUMOR VOLUME;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84881479223     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-2994-6     Document Type: Review

References (36)

1. Edge SB, Byrd DR, Compton CC, et al. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.
2. Rakha EA, Reis-Filho JS, Baehner F, et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res. 2010;12:207.
3. Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet. 2011;378(9805):1812-23.
4. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305:569-75.
5. Mansel R, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006;98:599-609.
6. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-52.
7. Sorlie T. Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer. 2004;40:2667-75.
8. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492-503.
9. Nielsen T, Hsu F, Jensen K, et al. Immunohistochemical and clinical characterization of the basal like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367-74.
10. Parikh RR, Yang Q, Higgins SA, Haffty BG. Outcomes in young women with breast cancer of triple-negative phenotype: the prognostic significance of CK19 expression. Int J Radiat Oncol Biol Phys. 2008;70:35-42.
11. Dawood S, Hu R, Homes MD, et al. Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study. Breast Cancer Res Treat. 2011;126:185-92.
12. Yi M, Giordano SH, Meric-Bernstam F, et al. Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database. Ann Surg Oncol. 2010;17(Suppl. 3):343-51.
13. Ruginǎ VG, Mihalcea D, Pricop F. The lymph nodes status - prognostic factor in breast cancer. Rev Med Chir Soc Med Nat Iasi. 2011;115:839-44.
14. Reyal F, Rouzier R, Depont-Hazelzet B, et al. The molecular subtype classification is a determinant of sentinel node positivity in early breast carcinoma. PLoS One. 2011;6:e20297.
15. Salhia B, Tapia C, Ishak EA, et al. Molecular subtype analysis determines the association of advanced breast cancer in Egypt with favorable biology. BMC Womens Health. 2011;11:44.
16. Singh Ranger G, Mokbel K. The evolving role of sentinel lymph node biopsy for breast cancer. Eur J Surg Oncol. 2003;29:423-5.
17. Parikh RR, Housman D, Yang Q, et al. Prognostic value of triple-negative phenotype at the time of locally recurrent, conservatively treated breast cancer. Int J Radiat Oncol Biol Phys. 2008;72:1056-63.
18. Moran MS, Yang Q, Harris LN, Jones B, Tuck DP, Haffty BG. Long-term outcomes and clinicopathologic differences of African-American versus white patients treated with breast conservation therapy for early-stage breast cancer. Cancer. 2008;113:2565-74.
19. Liu G, Yang Q, Haffty B, Moran M. Clinical-pathologic features and long-term outcomes of tubular carcinoma of the breast compared with invasive ductal carcinoma treated with breast conservation therapy. Int J Radiat Oncol Biol Phys. 2009;75:1304-8.
20. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest. 2000;80:1943-9.
21. Vargo JA, Beriwal S, Ahrendt GM, et al. Molecular class as a predictor of locoregional and distant recurrence in the neoadjuvant setting for breast cancer. Oncology. 2011;80:341-9.
22. Bland KI, Scott-Conner CE, Menck H, Winchester DP. Axillary dissection in breast-conserving surgery for stage I and II breast cancer: a National Cancer Data Base study of patterns of omission and implications for survival. J Am Coll Surg. 1999;188:586-95; discussion 95-6.
23. Barcenas CH, Wells J, Chong D, French J, Looney SW, Samuel TA. Race as an independent risk factor for breast cancer survival: breast cancer outcomes from the Medical College of Georgia Tumor Registry. Clin Breast Cancer. 2010;10:59-63.
24. Crabb SJ, Cheang MC, Leung S, et al. Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer. Clin Breast Cancer. 2008;8:249-56.
25. Van Calster B, Vanden Bempt I, Drijkoningen M, et al. Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive. Breast Cancer Res Treat. 2009;113:181-7.
26. Lee J, Suh Y, Shim B, Kim S. The incidence and predictor of lymph node metastasis for patients with T1mi breast cancer who underwent axillary dissection and breast irradiation: an institutional analysis. Jpn J Clin Oncol. 2011;41:1162-7.
27. Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol. 2006;37:1217-26.
28. Liu H, Fan Q, Zhang Z, Li X, Yu H, Meng F. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers. Hum Pathol. 2008;39:167-74.
29. Bortolini M, Genta F, Biacchiardi CP, Zanon E, Camanni M, Deltetto F. Axillary dissection in breast cancer patients with metastatic sentinel node: to do or not to do? Suggestions from our series. ISRN Oncol. 2011;2011:527904.
30. Hicks DG, Kushner L, McCarthy K. Breast cancer predictive factor testing: the challenges and importance of standardizing tissue handling. J Natl Cancer Inst Monogr. 2011;2011:43-5.
31. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471-4.
32. Anders CK, Deal AM, Miller CR, et al. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. Cancer. 2011;117:1602-11.
33. Kurian AW, Fish K, Shema SJ, Clarke CA. Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups. Breast Cancer Res. 2010;12:R99.
34. Dawood S, Ueno NT, Valero V, et al. Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Cancer. 2011;117:1819-26.
35. Calza S, Hall P, Auer G, et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res. 2006;8:R34.
36. Demirci S, Broadwater G, Marks LB, Clough R, Prosnitz LR. Breast conservation therapy: the influence of molecular subtype and margins. Int J Radiat Oncol Biol Phys. 2012;83:814-20.